{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Followed by Carboplatin\/Paclitaxel vs Chemotherapy, Both in Combination with Pembrolizumab as Neoadjuvant Therapy for Triple-Negative Breast Cancer (TNBC) or Hormone Receptor-low positive\/HER2-negative Breast Cancer","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-3-randomized-open-label-study-to-evaluate-the-efficacy-and-safety-of-sacituzumab-tirumotecan-sac-tmt-mk-2870-followed-by-carboplatin-paclitaxel-vs-chemotherapy-both-in-combination-with-p\/#breadcrumbitem"}]}